Sanctuary Advisors LLC Reduces Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Sanctuary Advisors LLC lowered its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 1.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,183 shares of the medical research company’s stock after selling 196 shares during the period. Sanctuary Advisors LLC’s holdings in Charles River Laboratories International were worth $3,172,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the business. Virtu Financial LLC bought a new stake in shares of Charles River Laboratories International in the 3rd quarter worth about $601,000. JPMorgan Chase & Co. grew its stake in Charles River Laboratories International by 21.6% in the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after purchasing an additional 85,759 shares in the last quarter. State Street Corp grew its stake in Charles River Laboratories International by 2.0% in the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after purchasing an additional 41,421 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Charles River Laboratories International by 7.6% in the third quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock valued at $9,064,000 after buying an additional 3,268 shares during the last quarter. Finally, Neo Ivy Capital Management acquired a new stake in Charles River Laboratories International during the third quarter valued at approximately $966,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Transactions at Charles River Laboratories International

In related news, CEO James C. Foster purchased 6,075 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the transaction, the chief executive officer now directly owns 183,639 shares of the company’s stock, valued at $30,302,271.39. This trade represents a 3.42 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, COO Birgit Girshick acquired 1,514 shares of the business’s stock in a transaction on Thursday, February 20th. The shares were bought at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the acquisition, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Price Performance

Shares of Charles River Laboratories International stock opened at $163.11 on Friday. Charles River Laboratories International, Inc. has a 52 week low of $150.79 and a 52 week high of $275.00. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The company’s 50-day moving average price is $172.84 and its two-hundred day moving average price is $188.09. The stock has a market cap of $8.34 billion, a PE ratio of 1,087.39, a price-to-earnings-growth ratio of 4.54 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business’s quarterly revenue was down 1.1% on a year-over-year basis. During the same period in the prior year, the business earned $2.46 earnings per share. As a group, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on CRL. TD Cowen lifted their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. Barclays decreased their price objective on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a report on Tuesday, February 18th. Evercore ISI increased their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. CLSA downgraded Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a report on Monday, November 18th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research report on Thursday. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, Charles River Laboratories International has a consensus rating of “Hold” and a consensus price target of $195.71.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).